Overview
- Bundeskartellamt approval cleared the way for BioNTech to open a public exchange offer for all remaining CureVac shares.
- CureVac investors can receive BioNTech American Depositary Shares, provisionally valuing their stock at about $5.46 per share.
- The final exchange ratio will be set five days before the offer’s planned expiration on December 3, 2025.
- CureVac’s management and supervisory boards advise shareholders to tender into the offer.
- BioNTech says the acquisition would add mRNA expertise for developing therapies for cancer and other diseases.